This review provides an update on the current clinical and preclinical understanding of
chemotherapy induced peripheral neuropathy (CIPN). The overview of the clinical syndrome …

Peripheral neuropathies are characterized by nerves damage and axonal loss, and they
could be classified in hereditary or acquired forms. Acquired peripheral neuropathies are …

In the central nervous system (CNS), astrocytes form networks interconnected by gap
junctions made from connexins of the subtypes Cx30 and Cx43. When unopposed by an …

Paclitaxel (PTX), which is widely used in the treatment of solid tumors, leads to dose
limitation because it causes peripheral neuropathy. This study was conducted to evaluate …

Bortezomib, a first-generation proteasome inhibitor widely used in chemotherapy for
hematologic malignancy, has effective anti-cancer activity but often causes severe …

Chemotherapy-induced peripheral neuropathy (CIPN) and associated neuropathic pain are
challenging complications of cancer treatment. Many of the major classes of …

Background Despite the increasing knowledge of the etiology of neuropathic pain, this type
of chronic pain is resistant to available analgesics in approximately 50% of patients and …

Background Chemotherapy-induced peripheral neuropathy (CIPN) is regarded as one of the
most common dose-limiting adverse effects of several chemotherapeutic agents, such as …

Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating and painful condition
seen in patients undergoing treatment with common agents such as vincristine, paclitaxel …

The burdensome condition of chemotherapy-induced peripheral neuropathy occurs with
various chemotherapeutics, including bortezomib, oxaliplatin, paclitaxel and vincristine. The …